Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 18/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.52 |
| ▸ | ULK1 | O75385 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27227971 | 1.00 | LRRK2 (0.53) | LRRK2CYP1A2ULK1 | |
| SCHEMBL30860843 | 0.89 | LRRK2 (0.52) | LRRK2CYP1A2ULK1 | |
| SCHEMBL27227903 | 0.89 | LRRK2 (0.52) | LRRK2CYP1A2ULK1 | |
| SCHEMBL30860782 | 0.88 | LRRK2 (0.51) | LRRK2CYP1A2ULK1 | |
| SCHEMBL27228045 | 0.88 | LRRK2 (0.51) | LRRK2CYP1A2ULK1 | |
| SCHEMBL30861094 | 0.86 | LRRK2 (0.62) | LRRK2 | |
| SCHEMBL27228523 | 0.86 | LRRK2 (0.62) | LRRK2 | |
| SCHEMBL30860933 | 0.83 | LRRK2 (0.54) | LRRK2CYP1A2ULK1 | |
| SCHEMBL27228527 | 0.83 | LRRK2 (0.54) | LRRK2CYP1A2ULK1 | |
| SCHEMBL30860864 | 0.81 | ULK1 (0.57) | LRRK2CYP1A2ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | LRRK2 1/4885CYP1A2 4674/4885ULK1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.